Carregant...
Off-label use of rituximab for systemic lupus erythematosus in Europe
OBJECTIVES: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy. METHODS:...
Guardat en:
| Publicat a: | Lupus Sci Med |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5013507/ https://ncbi.nlm.nih.gov/pubmed/27651920 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2016-000163 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|